BRCA1 and neoplasm: This study provides evidence that BRCA1/2-deficient and/or HRD cell lines comprise a heterogeneous group in which most (i.e., 82.4%) BRCA1/2-deficient cell lines have an HRP phenotype and therefore do not represent HRD tumor specimens.